; 7bit MedWatch logo MedWatch - The FDA Safety Information and Adverse Event Reporting Program The FDA is conducting a safety review based on study data suggesting there may be an increased risk of death from cancer in diabetic patients using Regranex (becaplermin) Gel, a skin product used to heal leg and foot ulcers. While the review is ongoing, the FDA recommends health care professionals discuss the potential risks and benefits of using Regranex with their patients. This early communication is in keeping with FDA's commitment to inform the public about its ongoing safety reviews of drugs. As soon as this review is complete, FDA will communicate the conclusions and recommendations to the public. Read the complete 2008 Safety Summary, including a link to the FDA Early Communication About An Ongoing Safety Review regarding this issue at: Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Buy onliner Preferences Page [ ]. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact This service is provided to you at no charge by U.S. Food & Drug Administration (FDA) [ ]. FDA [ ] HHS [ ] GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) . 5600 Fishers Lane . Rockville MD 20857 . 800-439-1420 ; 7bit FDA MedWatch- Regranex (becaplermin) Gel- Study Data Suggests Possible Increased Risk Of Death From Cancer In Diabetic Patients Using The Product body { font-size: 12px; font-family: arial, verdana, sans-serif; font-weight: normal; font-style: normal; } { color: gray; font-size: 10px; font-family: arial, verdana, sans-serif; font-weight: 100; } The FDA is conducting a safety review based on study data suggesting there may be an increased risk of death from cancer in diabetic patients using Regranex (becaplermin) Gel, a skin product used to heal leg and foot ulcers. While the review is ongoing, the FDA recommends health care professionals discuss the potential risks and benefits of using Regranex with their patients. This early communication is in keeping with FDA’s commitment to inform the public about its ongoing safety reviews of drugs. As soon as this review is complete, FDA will communicate the conclusions and recommendations to the public. Read the complete 2008 Safety Summary, including a link to the FDA Early Communication About An Ongoing Safety Review regarding this issue at: Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Buy onliner Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact This service is provided to you at no charge by U.S. Food & Drug Administration (FDA). GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420

... Back to listing 21

... Back to article 4007 | SITEMAP | Next to article 4009 ...

We would like to express our gratitude to all those who are kindly providing this unique content, especially to:

office@a3ides.com
olga@bemobile.md
tirlik@brainchildhunter.com
office@bemobile.md
sharuha@causeni.info
info@webconsulting.md
irina.gorea@bemobile.md
office@milieukontakt.nl
igor.romanyuk@bemobile.com.ua
yuri.sekretar@olympia.net.ua
info@tophost.md
webmoldova@yahoo.com
admin@bemobile.md
webmaster@bemobile.md
emil@a3ides.com
olea@bemobile.md
yuri.sekretar@bemobile.com.ua
contact@a3ides.com
info@a3ides.com
vitaliy.lozovskiy@bemobile.md
drugg83@yahoo.com
rector@usm.md
gaugash@usm.md
acad.rudic@mail.md
acadrudic@yahoo.com
veaceslav.vasilache@gmail.com
s.bakker@milieukontakt.nl
katea.melnicenco@gmail.com
mkoe.moldova@vox.md
musteata@doctor.com
renat.buga@ase.md
s.molenkamp@milieukontakt.nl
si_problemme@mail.ru
willem.tjebbe.oostenbrink@planet.nl

Tag cloud:

Regranex, Administration, ·, (becaplermin), patients., commitment, ongoing, communication, keeping, reviews, benefits, public., recommendations, conclusions, complete,, communicate, discuss, potential, diabetic, increased, suggesting, conducting, patients, product, complete, professionals, recommends, ulcers., ongoing,, Summary,,

Similar listing on: